Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) just unveiled an update.
GenFleet Therapeutics has announced promising results from its phase I/II trial of GFH375, an oral inhibitor targeting the KRAS G12D mutation in pancreatic ductal adenocarcinoma (PDAC) patients. The data, presented at the ESMO Congress 2025, showed a 40.7% objective response rate and a 96.7% disease control rate among heavily pretreated patients, with a manageable safety profile. These findings highlight GFH375’s potential as a significant treatment option for patients with advanced PDAC, addressing a critical unmet medical need and strengthening GenFleet’s position in the oncology market.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a biotechnology company focused on developing innovative cancer therapies. The company specializes in creating targeted treatments for specific genetic mutations, such as the KRAS G12D mutation, which is prevalent in pancreatic cancer.
Average Trading Volume: 3,450,732
For a thorough assessment of 2595 stock, go to TipRanks’ Stock Analysis page.